Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2000-05-08
2003-10-07
Pryor, Alton (Department: 1616)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
Reexamination Certificate
active
06630320
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to a method for reducing hypertension in mammals with specific hydrolysates obtained by the enzymatic conversion of whey proteins.
Hypertension has been reported to be the most important cause of human deaths in industrialized countries. (See, for example, Laragh, J. H., 1979,
L'hypertension. Recherche,
105 (10): 1068-1076) Nearly 30% of the fatalities among adults would result from hypertension or from its renal, coronary or neurological complications. The elucidation of the physiological mechanisms responsible for hypertension has lead to the introduction of several pharmaceuticals for the treatment of hypertension and/or its symptoms, which include increased heart rate and increased blood pressure.
It would be desirable to identify additional materials capable of treating hypertension or its symptoms, especially materials that can be easily employed as part of a simple regimen such as being included in food items.
REFERENCES:
patent: 3857966 (1974-12-01), Feldman et al.
patent: 3932672 (1976-01-01), Pour-El et al.
patent: 3970520 (1976-07-01), Feldman et al.
patent: 4001437 (1977-01-01), Jaeggi et al.
patent: 4107334 (1978-08-01), Jolly
patent: 4154675 (1979-05-01), Jowett et al.
patent: 4218490 (1980-08-01), Phillips et al.
patent: 4293571 (1981-10-01), Olofsson et al.
patent: 4293583 (1981-10-01), Farr et al.
patent: 4427658 (1984-01-01), Maubois et al.
patent: 4482574 (1984-11-01), Lee
patent: 4486413 (1984-12-01), Wiesenberger et al.
patent: 4847096 (1989-07-01), Mellqvist et al.
patent: 4981704 (1991-01-01), Thibault
patent: 5039532 (1991-08-01), Jost et al.
patent: 5322773 (1994-06-01), Kaneko et al.
patent: 5369015 (1994-11-01), Yoshikawa et al.
patent: 5405637 (1995-04-01), Martinez et al.
patent: 5589357 (1996-12-01), Martinez et al.
patent: 5695796 (1997-12-01), Yamamoto et al.
patent: 5744179 (1998-04-01), Shimamura et al.
patent: 5854029 (1998-12-01), Yamamoto
patent: 5869444 (1999-02-01), Klein
patent: 5882705 (1999-03-01), Sato et al.
patent: 5952193 (1999-09-01), Shimamura et al.
patent: 0 474 506 (1992-03-01), None
patent: 04-082898 (1992-03-01), None
patent: 04282398 (1992-10-01), None
patent: 04282400 (1992-10-01), None
patent: 04-282400 (1992-10-01), None
patent: 06345664 (1994-12-01), None
patent: 08-269088 (1996-10-01), None
patent: WO 99/65326 (1999-12-01), None
Bachelard, H. and G. Drolet, Cardiovascular responses to paraventricular (PVN) injections of opioid agonists in conscious rats;Abstract Society for Neuroscience, 18: 1175; 1992. (Copy ordered).
Bachelard H. and M. Pitre, Regional haemodynamic effects of &mgr;-, &dgr;-, &kgr;-opioid agonists microinjected into the hypothalmic paraventricular nuclei of conscious, unrestrained rats; Br.J. Pharmacol, 15:613-621, 1995. (Copy ordered).
Laragh; “L'hypertension”;Recherche, 105 (10): 1068-1076; Nov. 1979.
Pearce; “Whey Protein Recovery and Whey Protein Fractionation”;Whey and Lactose Processing, Zadow, J. G., ed.;271-316, London 1992.
Pitre, M., A. Nateau and H. Bachelard, Insulin sensitivity and hemodynamic responses to insulin in Wistar-Kyoto and spontaneously hypertensive rats,Am. J. Physiol.271: E658-E668, 1996. (Copy ordered).
Pitre, M., H. Gaudreault, M. Santure, A Nadeau, and H. Bachelard; Isradipine and insulin sensitivity in hypertensive rats;Am. J. Physiol., 39:E1038-E1048, 1999. (Copy ordered).
Bachelard, H., M. Pitre and A. Lessard; Mechanisms of the Regional Hemodynamic Effects of a &mgr;-Opiod Receptor Agonist Microinjected into the Hyothalamic Paraventricular Nuclei of Conscious Unrestrained Rats;JPET280:460-470, 1997.
Santuré, M. Pitre, N. Aaudreault, A. Marette, A. Nadeau and H. Bachelard; Effect of metformin on the vascular and glucose metabolic actions of insulin in hypertensive rats;Am. J. Physio Gastrointest Liver Physiol278:G682-G692, 2000.
Hawley's Condensed Chemical Dictionary, Richard J. Lewis, Sr., 13th Edition, 937 (1997).
“Davisco Foods International, Advitech Solutions Join Forces to Produce Whey Protein Hydrolyzate”,Davisco Press Release(1998).
Davisco “Nominated for Prestigious International Award for its Patented Hypertension-Reducing Whey Protein”,Davisco Press Release(1999).
Abubakar et al., “Structural Analysis of New Antihypertensive Peptides Derived from Cheese Whey Protein by Proteinase K Digestion”,Journal of Dairy Science,813131-3138 (1996).
Abubakar et al. “New Derivation of the Inhibitory Activity Against Angiotensin Converting Enzyme (ACE) from Sweet Cheese Whey”,Tohoku Journal of Agricultural Research,471-8 (1996).
Cushman et al., “Spectrophotometric Assay and Properties of the Angiotensin-Converting Enzyme of Rabbit Lung”,Biochemical Pharmacology, 201637-1648 (1971).
Ferreira et al., “Isolation of Bradykinin-Potentiating Peptides fromBothrops jararacaVenom”,Biochemistry, 92583-2593 (1970).
Kohmura et al., “Inhibition of Angiotensin-Converting Enzyme by Synthetic Peptides of Human beta-Casein”,Agric. Biol. Chem., 532107-2114 (1989).
Maruyama et al., “A Peptide Inhibitor of Angiotensin I Converting Enzyme in the Tryptic Hydrolysate of Casein”,Agric. Biol. Chem., 461393-1394 (1982).
Maubois et al., “Les Peptides du Lait a Activite Physiologique III. Peptides du Lait a Effet Cardiovasculaire: Activities Antithrombotique et Antihypertensive”,Lait, 71249-255 (1991).
Mullally et al., “Identification of a Novel Angiotensin-I-Converting Enzyme Inhibitory Peptide Corresponding to a Tryptic Fragment of Bovine beta-Lactoglobulin”,FEBS Letters, 40299-101 (1997).
Oshima et al., “Peptide Inhibitors of Angiotensin I-Converting Enzyme in Digests of Gelatin by Bacterial Collagenase”,Biochemical et Biophysica Acta, 566128-137 (1979).
Takano, “Milk Derived Peptides and Hypertension Reduction”,Int. Dairy Journal, 8375-381 (1998).
Ju et al., “Effects of Limited Proteolysis on Gelation and Gel Properties of Whey Protein Isolate”,Journal of Dairy Science, 78, 2119-2128 (1195).
Otte et al., “Effects of Limited Proteolysis on the Microstructure of Heat-Induced Whey Protein Gels at Varying pH”,Journal of Dairy Science, 79, 782-790 (1996).
Davis Martin E.
Gauthier Sylvie
Pouliot Yves
Rao Anand
Devisco Foods International, Inc.
Pryor Alton
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Treatment of hypertension in mammals with hydrolyzed whey... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hypertension in mammals with hydrolyzed whey..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hypertension in mammals with hydrolyzed whey... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3134678